Cite
HARVARD Citation
Cork, M. et al. (2021). Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study. British journal of dermatology. pp. 857-870. [Online].